News

Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026

Stelexis Therapeutics Closes $43 million Series A to Expand Novel Platform Focused on Cancer Interception

27th January 2019